上海交大赵大海关于新冠疫情第51次在电视台访谈评论:新冠疫苗研制遭遇短期困难不意外

上海交通大学国际与公共事务学院博士生导师、上海交通大学-耶鲁大学卫生政策联合研究中心执行主任赵大海,自新冠肺炎疫情暴发以来,对于新冠疫情暴发、防控以及医疗卫生体制改革第20次在上海电视台进行访谈评论,也是第51次在央视、上视进行访谈评论。在2020年9月9日,赵大海在上海电视台新闻综合频道的《新闻夜线》节目,就牛津大学和阿斯利康决定暂停新冠疫苗实验进行了访谈评论。现将访谈内容摘录如下。

主持人:那么究竟是怎样的不良反应,会让英国牛津大学和阿斯利康决定暂停新冠疫苗的实验呢?那这是否意味着英国方面的新冠疫苗研制就受阻了呢?我们来听一下专家的分析。

赵大海:一般不会,在这个实验当中暴露出来的问题应该是在它预料之外。而且这个问题已经超过了原先设计疫苗所预期的副作用,因此,需要重新来修正疫苗的设计。

主持人:专家指出新冠疫苗研制对于全世界而言都是第一次,某一团队研制遭遇短期的困难,它并不意味着全球疫苗研发进程的停滞。

赵大海:冠状病毒虽然我们人类已经遇到多次,但是之前我们都没有进行过冠状病毒疫苗的研发,所以应该讲是人类的第一次尝试,因此在研制过程当中出现一些困难,可以讲是意料之中的。

主持人:根据世卫组织的最新统计数据,截至9月3号,全球有34款产品处于临床研究阶段,142款产品处于临床前阶段,进入三期临床的产品有8项,其中我国有三款灭活疫苗和一款腺病毒载体疫苗进入全球三期。

供稿者:国务学院

日期:2020年9月10日


Dahai Zhao' 51th comments on TV during the Pandemic: It is not surprising that the development of COVID-19 vaccine encounters short-term difficulties

Dahai Zhao, a doctoral supervisor at School of International and Public Affairs of Shanghai Jiao Tong University and Executive Director of Shanghai Jiao Tong University-Yale University Joint Research Center for Health Policy, has been interviewed by ShanghaiTV for the 20th time (the 51th time by CGTN / ShanghaiTV) since the COVID-19 pandemic. On September 9, 2020, Zhao commented on Oxford University and Astrazeneca have decided to suspend COVID-19 trials on “News Night-line” of ShanghaiTV. 

Anchor: So what kind of adverse reaction caused the University of Oxford and AstraZeneca to decide to suspend the trial of the new crown vaccine? Does this mean that the development of a new crown vaccine in the UK is blocked? Let's listen to the expert's analysis.

Zhao Dahai: Generally not. The problems exposed in this experiment should be beyond its expectations. Moreover, this problem has exceeded the expected side effects of the original vaccine design. Therefore, the vaccine design needs to be revised.

Anchor: Experts pointed out that the development of the new crown vaccine is the first time for the world. A certain team has encountered short-term difficulties in the development, which does not mean that the global vaccine development process has stalled.

Zhao Dahai: Although we humans have encountered the coronavirus many times, we have not conducted the research and development of a coronavirus vaccine before, so it should be the first attempt by human beings. Therefore, there have been some difficulties in the development process. Expected.

Anchor: According to the latest statistics of the WHO, as of September 3, there are 34 products in the clinical research phase, 142 products in the pre-clinical phase, and 8 products in phase III clinical trials, including three in my country Inactivated vaccine and an adenovirus vector vaccine entered the third phase of the world.

Contributor: SIPA, SJTU

Data: September 10, 2020


沪交ICP备20200053
Copyright © 2020上海交大—耶鲁大学卫生政策联合研究中心/SJTU-Yale Joint Center for Health Policy